Discounted Cash Flow (DCF) Analysis Levered
Mithra Pharmaceuticals SA (MITRA.BR)
3.11 €
-0.04 (-1.27%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 46.25 | 57.88 | 96.52 | 9.03 | 22.67 | 31.30 | 43.21 | 59.67 | 82.38 | 113.75 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -34.92 | 3.54 | -46.83 | -80.02 | -74.39 | -83.39 | -115.15 | -158.98 | -219.51 | -303.08 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -12.20 | -10.10 | -15.45 | -16.23 | -21.18 | -20.85 | -28.78 | -39.74 | -54.87 | -75.76 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -47.12 | -6.56 | -62.28 | -96.26 | -95.57 | -104.24 | -143.93 | -198.72 | -274.38 | -378.84 |
Weighted Average Cost Of Capital
Share price | $ 3.11 |
---|---|
Beta | 0.551 |
Diluted Shares Outstanding | 107.49 |
Cost of Debt | |
Tax Rate | 5.57 |
After-tax Cost of Debt | 5.03% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 6.230 |
Total Debt | 220.72 |
Total Equity | 334.28 |
Total Capital | 555 |
Debt Weighting | 39.77 |
Equity Weighting | 60.23 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | 46.25 | 57.88 | 96.52 | 9.03 | 22.67 | 31.30 | 43.21 | 59.67 | 82.38 | 113.75 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -34.92 | 3.54 | -46.83 | -80.02 | -74.39 | -83.39 | -115.15 | -158.98 | -219.51 | -303.08 |
Capital Expenditure | -12.20 | -10.10 | -15.45 | -16.23 | -21.18 | -20.85 | -28.78 | -39.74 | -54.87 | -75.76 |
Free Cash Flow | -47.12 | -6.56 | -62.28 | -96.26 | -95.57 | -104.24 | -143.93 | -198.72 | -274.38 | -378.84 |
WACC | ||||||||||
PV LFCF | -98.57 | -128.70 | -168.04 | -219.40 | -286.45 | |||||
SUM PV LFCF | -901.16 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 5.75 |
Free cash flow (t + 1) | -386.42 |
Terminal Value | -10,304.49 |
Present Value of Terminal Value | -7,791.56 |
Intrinsic Value
Enterprise Value | -8,692.72 |
---|---|
Net Debt | 187.85 |
Equity Value | -8,880.57 |
Shares Outstanding | 107.49 |
Equity Value Per Share | -82.62 |